Hold with dual re-engagement triggers; define entry around $292.94 confirmation or $264-269 pullback before upgrading
Hold maintained. The Q2 FCF inflection ($555M → $2.19B YoY) and 52% EPS growth with 35.2% ROE are genuinely constructive for a $320-330 price target, but momentum (MACD weakest reversal signal), trend structure (50 SMA broken, three lower highs intact), and macro (86% no-cut probability) all argue against Overweight. Trigger A (25% Tranche 1 at $292.94 breakout) or Trigger B (33% Tranche 1 at $264-269 retest) resolve the aggressive/conservative split; hard stop at $260 weekly close. This is a buyable thesis on better terms — current terms are not yet those terms.
| Position | Action |
|---|---|
| Confirmed close above $292.94 on above-average volume | Initiate Tranche 1 (25% of target position, ~0.75% of portfolio) |
| Retest of $264-269 with reversal candle | Initiate Tranche 1 (33% of target position, preferred better-entry path) |
| Weekly close below $260 | Hard stop — exit any position regardless of trigger fired |
TXN is mid-cycle recovery with ~20% EPS growth remaining before matching the 2022 peak, FCF inflecting 4x year-over-year, and institutional momentum creating a buyable correction at the 10 EMA ($280).
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $280.19 | bullish |
| close_50_sma | $292.94 | bearish |
| close_200_sma | $227.40 | bullish |
| rsi | 47.33 | neutral |
| macd | -4.03 | neutral |
| macds | -4.74 | neutral |
| macdh | +0.70 | bullish |
| boll | $282.74 | neutral |
| boll_ub | $300.64 | neutral |
| boll_lb | $264.84 | bullish |
| atr | 12.01 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Successful retest of $264-269 with reversal candle
Then: Initiate Tranche 1 (33% of target); delivers 1.5:1 reward/risk ratio
Industrial analog demand confirms secular growth thesis
EV: +4-5% near-term (target: reclaim 50 SMA at $292.94); structural target $320+ on cyclical recovery extension
TXN's "mid-cycle" framing is a dangerous trap; margins have 930bps downside to prior-cycle averages, the 27x forward P/E is an optical illusion based on consensus EPS that typically overshoots by 10-20%, technicals show a structural breakdown with three lower highs, and a hawkish Fed/no-cut macro regime creates asymmetric risk that makes the current risk-reward unfavorable.
EV: ~$272 (below current $280.44) · concedes: Long-term uptrend is real; shorting into it 'has killed plenty of bears'; Fundamentals are good; Not calling for a short position; Waiting at $264-269 with confirmed reversal candles is the 'buyable correction' the bull describes
→ vs conservative: Anchoring thesis on short-term price action (50 SMA break, bearish engulfing candle on August 10) while ignoring structural reality; conflating 16% pullback within secular trend with trend break; 200 SMA at $227 proves uptrend intact
→ vs conservative: Macro fears (Polymarket 86% odds of zero Fed cuts 2026, Hormuz oil spikes) overblown for TXN specifically; fortress balance sheet (current ratio 4.86, ROE 35.2%) defends capital in choppy markets regardless of 10-year yield
→ vs conservative: 'Wait for confirmation' approach means paying $310 instead of $280; perfect entry doesn't exist; biggest risk is sitting on sidelines watching TXN reclaim $310, $320, beyond
→ vs neutral: Fair value at $272 using EV math is static model applied to company with earnings inflecting at 4x pace on FCF; EV math anchored to trailing numbers that are about to look quaint
→ vs neutral: Momentum and catalyst timing matter more than static fair value; FCF inflection and capex normalization story haven't fully played out yet
→ vs conservative: Bear math at $272 doesn't change need to be in name to capture move from $280 back to $330-plus; every day waiting for perfect confirmation is day market re-prices FCF inflection
| vwma | $279.10 | neutral |
Support: 280.19 · 275.74 · 269.04 · 264.84 · 227.4 | Resistance: 286.08 · 292.94 · 300.64 · 309.87 · 332.33
TXN exhibits a mixed technical picture: long-term uptrend intact (price 23% above 200 SMA at $227.40), but medium-term weakness (price $12.50 below 50 SMA at $292.94). Short-term, price is sitting at the 10 EMA pivot ($280.19) following a bearish engulfing reversal on Aug 10 (open $288.07 → close $280.44). RSI neutral at 47.33, MACD histogram just turned positive at +0.70 (early bullish divergence). Price in lower half of Bollinger Band range ($264.84-$300.64). Recommendation: HOLD with defensive bias—avoid new longs at current levels; watch for reclaim above $292.94 or retest of $264-269 support zone for better risk/reward entries.
Market Cap
$256.1B
TTM P/E
42.62x
Forward P/E
26.95x
PEG Ratio
1.26
Price/Book
14.22x
Dividend Yield
1.99%
Beta
1.325
52-Week High
$334.03
52-Week Low
$152.73
Q2 2026 Revenue
$5,463M
Q2 2026 Gross Margin
61.4%
Q2 2026 Operating Margin
42.6%
Q2 2026 Diluted EPS
$2.14
TTM Diluted EPS
$6.58
FY2025 Revenue
$17,682M
FY2024 Revenue
$15,641M
FY2022 Revenue (Peak)
$20,028M
FY2025 Gross Margin
57.0%
FY2022 Gross Margin (Peak)
68.8%
FY2025 Diluted EPS
$5.45
FY2022 Diluted EPS (Peak)
$9.41
TTM Revenue
$19,453M
TTM Net Income
$6,017M
TTM Operating Income
$8,283M
TTM Free Cash Flow
$3.55B
Q2 2026 Free Cash Flow
$2.19B
Q2 2026 Operating Cash Flow
$2.70B
Q2 2026 Capex
$514M
FY2025 Capex
$4.55B
FY2024 Capex
$4.82B
FY2023 Capex
$5.07B
Q2 2026 Cash & ST Investments
$7,001M
Q2 2026 Total Current Assets
$15,757M
Q2 2026 Inventory
$4,605M
Q2 2026 Net PPE
$11,911M
Q2 2026 Gross PPE
$17.86B
Q2 2026 Total Assets
$35,882M
Q2 2026 Long-Term Debt
$12,903M
Q2 2026 Net Debt
$10,392M
Q2 2026 Stockholders' Equity
$18,007M
Cumulative Retained Earnings
$53.2B
Q2 2026 Working Capital
$12,513M
Q2 2026 Current Ratio
4.86
Debt-to-Equity Ratio
0.78
Net Debt/Equity
0.58
TTM Profit Margin
31.1%
TTM Operating Margin
42.6%
TTM ROE
35.2%
TTM ROA
13.1%
FY2025 R&D Expense
$2,083M
FY2024 R&D Expense
$1,959M
FY2022 R&D Expense
$1,670M
FY2025 Dividends Paid
$5.0B
FY2025 Buybacks
$1.48B
FY2024 Dividends Paid
$4.80B
FY2022 Buybacks
$3.62B
Annual Dividend Per Share
~$5.40
Depreciation FY2025
$2.0B
FY2026 Consensus EPS
$10.40
50-Day Moving Average
$294.95
200-Day Moving Average
$229.11
vs 200-day MA
+22%
vs 50-day MA
-5%
Strengths
Concerns
Texas Instruments is demonstrating a strong cyclical recovery in 2026 with Q2 revenue up 22.8% YoY and EPS up 51.8% YoY, as the analog semiconductor cycle moves from the FY2024 trough toward the FY2022 peak. The company maintains elite profitability metrics with 35.2% ROE and 42.6% operating margin, driven by its vertically integrated manufacturing model and pricing power in analog chips. Free cash flow is inflecting sharply as capex normalizes from $1.3B to $514M quarterly, while the fortress balance sheet (current ratio 4.86, debt-to-equity 0.78) supports continued capital returns through dividends and buybacks. The primary risk is premium valuation at 42.6x TTM P/E, though the forward P/E of 27x on consensus FY2026 EPS of $10.40 appears more reasonable if the recovery is sustained into 2027.
Macro: Risk-off on Aug 10 as Strait of Hormuz reopening hopes fade, pushing crude and Treasury yields higher; Polymarket prices 86% odds of zero Fed cuts in 2026 (up 3pp in one week, more hawkish); U.S. recession odds 8% (low/soft landing), UK 17% (+1.5pp WoW), Japan 28% (−6.5pp WoW); FRED macro data unavailable (API key not set); directional read on rates/inflation sourced from Polymarket and news flow consistent with higher-for-longer regime.